ProteaPex Therapeutics, LLC and Philadelphia College of Osteopathic Medicine
EB 2018
ProteaPex Therapeutics, a faculty start-up of Philadelphia College of Osteopathic Medicine, has developed a platform technology of therapeutics, the Extracellular Matrix Protection Factors (ECPFs), to treat diseases with underlying extracellular matrix degradation as a causative factor. The ECPFs are a novel class of locally-delivered therapeutics that act as a bumper to reversibly block enzyme actions on specific targets. ProteaPex is developing their lead, game-changing, osteoarthritis treatment, Pexagen, through the animal health market as a gateway to the lengthier and more costly human therapeutic development path.